King D Michael
Department of Radiology, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, London, UK.
Cancer Imaging. 2005 Dec 15;5(1):150-6. doi: 10.1102/1470-7330.2005.0109.
Gastrointestinal stromal tumours (GISTs) comprise a group of smooth muscle mesenchymal alimentary tract tumours of variable malignancy. Recently, the pathophysiology and radiology of these tumours has generated enormous interest following the discovery of a specific, highly effective, chemotherapeutic agent in the form of ST-571 (Imatinib; Glivec, Novartis, Frimley UK). At the time of this review, 106 patients with malignant gastrointestinal stromal tumours seen at the Royal Marsden Hospital have been entered into trials examining the efficacy of varying doses of Imatinib. Burkill et al., also from the Royal Marsden Hospital, have previously reported the distribution, imaging features and pattern of metastatic spread of these tumours (Burkill GJ, Badran M, Al-Muderis O et al. Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology 2003; 226: 527-32). This new review re-examines the radiological features of GISTs at presentation and well as their changed imaging features following treatment with Imatinib.
胃肠道间质瘤(GISTs)是一组具有不同恶性程度的平滑肌间质性消化道肿瘤。最近,在发现了一种名为ST-571(伊马替尼;格列卫,诺华公司,英国弗里姆利)的特效化疗药物后,这些肿瘤的病理生理学和放射学引起了极大的关注。在本次综述撰写之时,皇家马斯登医院收治的106例恶性胃肠道间质瘤患者已进入试验,以检验不同剂量伊马替尼的疗效。同样来自皇家马斯登医院的伯基尔等人此前已报道过这些肿瘤的分布、影像学特征及转移扩散模式(Burkill GJ, Badran M, Al-Muderis O等。恶性胃肠道间质瘤:分布、影像学特征及转移扩散模式。放射学杂志2003;226:527 - 32)。这篇新综述重新审视了GISTs初诊时的放射学特征以及使用伊马替尼治疗后的影像特征变化。